Build a bioanalytical strategy that will ensure speed and agility
In order to build a robust bioanalytical strategy for your drug discovery program, it’s crucial to collaborate with a partner who possesses both industry expertise and a track record of operational success.
Aliri by the numbers:
- 48-hour turnarounds in discover
- 150 biological fluids & tissues
- 1 million samples analyzed
Our team of seasoned scientists, industry experts, program managers, and quality specialists can help you develop a successful bioanalytical strategy that will maximize the growth of your drug discovery investments. Work with us to gain access to a robust suite of mass spectrometry platforms, achieve quality data to quickly file your IND, NDA and CTA, and forecast potential roadblocks that may cause delays in your project’s timeline.
Download our factsheet to explore our offerings, platforms, compounds, regulations and more.
Non-proprietary Assays
There are many factors to consider when choosing a bioanalysis partner for your project. One of which should be finding a company with the scientific expertise and resources you need to move forward with speed, accuracy, and certainty. One of those resources being a large assortment of assays.
Aliri has over 1500 non-proprietary assays that allow us to measure a wide variety of compounds using our advanced technology. Our expertise will advance your molecule with speed and agility!
Our species matrices include:
- Human Plasma
- Human Serum
- Human Whole Blood
- Whole Blood
- Human Dried Blood Spot
- Human Urine
Most common Assays:
- Budesonide
- Bupropion, Hydroxybupropion
- Diclofenac
- Naloxone
- Naltrexone/ Naltrexol
- Pregabalin
- Riluzole
- Rosuvastatin
- Rosuvastatin/ Desmethyl Rosuvastatin/ Rosuvastatine Lactone
- Tenofovir
- Tiotropium
Download our latest comprehensive list of non-proprietary assays available for you.